Harmony Biosciences to acquire Zynerba Pharma and with it Zygel which is in Phase III for Fragile X syndrome
Harmony Biosciences Holdings, Inc. a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc., a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS)